drugset / Trial / NCT04062032
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an open label phase II pilot study assessing the metabolomic and inflammatory effects of oral aspirin (ASA) in human subjects at risk for melanoma.
Timeline
- Start
- 2016-09-27
- Primary completion
- 2019-02-27
- Completion
- 2019-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | Oral |
| Subject | Aspirin | Small molecule | 325 mg | Oral |